• Pieris and Genentech sign $1.4bn respiratory and ophthalmology deal pharmaceutical-technology
    May 27, 2021
    Pieris Pharmaceuticals and Roche Group subsidiary Genentech have signed a multi-programme research partnership and licence agreement worth approximately $1.42bn to discover, develop and market respiratory and ophthalmology therapies.
PharmaSources Customer Service